It is indeed. Surprisingly, no one (so far) has voted for the Tocetrapib choice in the iHub PFE survey. 2006 should see more clinical results released.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”